Corticotropin-releasing factor (CRF) neurons in the paraventricular nucleus (PVN) represent the primary hypothalamic population that orchestrates the stress response via the hypothalamic-pituitary-adrenal (HPA) axis. These neurosecretory neurons synthesize and release CRF (also called CRH - corticotropin-releasing hormone), which acts on the anterior pituitary to stimulate ACTH release, ultimately leading to glucocorticoid secretion from the adrenal cortex.
| Property |
Value |
| Category |
Neurosecretory neurons |
| Gene |
CRH (corticotropin releasing hormone) |
| Protein |
Corticotropin-Releasing Factor (CRF/CRH) |
| Neuropeptide |
CRF (41 amino acids) |
| Brain Region |
Paraventricular Nucleus (PVN) of hypothalamus |
| Pituitary Target |
Anterior pituitary corticotrophs |
The CRH gene encodes the prepro-CRF precursor:
- Location: Chromosome 8q13 in humans
- Preproprotein: 196 amino acids
- Processing: Signal peptide removal, peptide cleavage
- Post-translational modifications: Amidation, pyroglutamation
CRF is a 41-amino acid neuropeptide:
- Structure: Linear peptide with amidated C-terminus
- Homology: Related to urotensin, sauvagine
- Receptors: CRF1R (CRFR1), CRF2R (CRFR2)
- Binding: High affinity for CRF1R, lower for CRF2R
Two CRF receptor subtypes exist:
CRF1R (CRFR1):
- Gq-coupled GPCR
- Predominant in pituitary and cortex
- Mediates stress response
- Targeted by clinical drugs
CRF2R (CRFR2):
- Gi/o-coupled
- Expressed in hypothalamus, heart, GI tract
- May have anxiolytic effects
- Less clinically targeted
The PVN is located in the anterior hypothalamus:
- Dorsal: Third ventricle
- Ventral: Median eminence
- Lateral: Dorsomedial hypothalamus
- Rostral: Suprachiasmatic nucleus
- Caudal: Posterior hypothalamus
The PVN contains distinct neuronal populations:
Parvocellular neurons (stress response):
- Neurosecretory CRF neurons
- Project to median eminence
- Control pituitary function
- Autonomic integration
Magnocellular neurons (vasopressin/oxytocin):
- Vasopressin neurons
- Oxytocin neurons
- Project to posterior pituitary
- Blood volume regulation
CRF neurons receive input from:
- Amygdala: Stress-related signals
- Hippocampus: Feedback regulation
- Prefrontal cortex: Cognitive stress
- Brainstem: Physiological stressors
- Hypothalamic nuclei: Metabolic signals
CRF neurons project to:
- Median eminence (portal system)
- Brainstem (autonomic centers)
- Limbic structures (behavioral effects)
- Spinal cord (sympathetic outflow)
CRF neurons are the apex of the HPA axis:
- Stress detection: Multiple afferent inputs
- CRF release: Into median eminence portal system
- ACTH stimulation: Anterior pituitary corticotrophs
- Cortisol release: Adrenal cortex
- Feedback: Hippocampal and hypothalamic inhibition
Phasic release:
- Diurnal rhythm (peak at morning)
- Pulsatile secretion (hourly)
- Stress-induced activation
Tonically active:
- Basal secretion maintained
- Tonic inhibition by glucocorticoids
- Reset by stress
CRF neurons respond to:
- Glucocorticoids: Negative feedback
- Cytokines: Inflammatory signals
- Metabolic signals: Leptin, ghrelin
- Neurotransmitters: GABA (inhibitory), glutamate (excitatory)
CRF orchestrates physiological stress responses:
- Neuroendocrine: HPA axis activation
- Autonomic: Sympathetic activation
- Behavioral: Anxiety, fear, arousal
- Metabolic: Energy mobilization
- Immune: Leukocyte redistribution
CRF modulates:
- Anxiety: Anxiogenic effects
- Fear: Enhanced fear conditioning
- Arousal: Increased vigilance
- Exploration: Reduced exploration
- Feeding: Appetite suppression (acute)
CRF influences:
- Heart rate: Increased
- Blood pressure: Elevated
- Respiration: Increased
- GI motility: Decreased
- Pupil dilation: Sympathetic
CRF system develops early:
- Embryonic: CRH expression in developing hypothalamus
- Perinatal: HPA axis maturation
- Postnatal: Stress axis programming
- Critical periods: Early life stress effects
Early life experiences program CRF function:
- Maternal care: Low care increases CRF expression
- Prenatal stress: Alters HPA axis set-point
- Neonatal handling: Reduces stress reactivity
- Early adversity: Increases vulnerability
CRF alterations in AD:
- CRF depletion: Reduced hypothalamic CRF
- HPA axis dysregulation: Cortisol elevation
- Cognitive effects: Glucocorticoid neurotoxicity
- Amyloid interaction: CRF modulates Aβ processing
- Therapeutic targeting: CRF receptor modulators
Research findings:
- Elevated cortisol in AD patients
- CRF neuron loss in some studies
- Glucocorticoid cascade hypothesis
In PD:
- HPA axis hyperactivity: Common in PD
- CRF alterations: Dopamine-CRF interactions
- Stress sensitivity: Enhanced in PD
- L-DOPA effects: May affect CRF
- Non-motor symptoms: Fatigue, depression linked
CRF in depression:
- CRF hyperactivity: Elevated CSF CRF levels
- HPA axis dysfunction: Dexamethasone non-suppression
- Stress vulnerability: CRF system changes
- Treatment effects: Antidepressants modulate CRF
- Therapeutic targeting: CRF1 antagonists
- CRF system upregulation: In anxiety
- CRF1 involvement: Anxiogenic effects
- Treatment: CRF1 antagonists in development
- Gene variants: CRH polymorphisms and anxiety
- CRF-producing tumors: Pituitary adenomas
- ACTH hypersecretion: From CRF stimulation
- Hypercortisolism: Systemic effects
- Treatment: Surgery, medical management
- CRF and seizures: Complex relationship
- Proconvulsant effects: At high levels
- Anticonvulsant potential: CRF2 activation
- Stress-seizure link: CRF mediation
CRF receptors are therapeutic targets:
CRF1 antagonists:
- Pexacerfont (experimental)
- Verucerfont (experimental)
- Antalarmin (research)
CRF2 agonists:
- Stresscopin (urocortin)
- Potential anxiolytics
- Anxiety disorders: CRF1 antagonists
- Depression: CRF modulation
- Cushing's: CRF receptor blockade
- Epilepsy: CRF2 agonists
- Stress-related disorders: Various targets
- Blood-brain barrier penetration
- Receptor subtype selectivity
- Side effect profiles
- Species differences
- CRF measurement: RIA, ELISA
- mRNA detection: In situ hybridization
- Immunohistochemistry: Protein localization
- Electrophysiology: Neuronal recording
- Behavioral testing: Stress paradigms
- CRF transgenic mice: Overexpression
- CRF knockout mice: Deletion studies
- CRF receptor mutants: Selective ablation
- Stress models: Chronic stress paradigms
- Vale W, et al. Characterization of a ovine hypothalamic peptide. Science. 1981
- Koehnle TJ, et al. Corticotropin-releasing factor. Endocr Rev. 2003
- Bale TL, et al. The CRF system. Nat Rev Neurosci. 2002
- Holsboer F. The rationale for CRF antagonists. Eur Neuropsychopharmacol. 2003
- Sapolsky RM. Stress and cognition. Nat Rev Neurosci. 2015
- Deussing JM, et al. CRF and CRF receptors. Handb Exp Pharmacol. 2013
- Laryea G, et al. CRF in Alzheimer's disease. J Mol Neurosci. 2015
- Jankord R, et al. Stress and Parkinson's disease. Front Neuroanat. 2010
- Herman JP, et al. Neural pathways of stress integration. Behav Neurosci. 2012
- Stengel A, et al. CRF and the gut. Curr Opin Pharmacol. 2013